Standard Biotools (LAB) Cash from Investing Activities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash from Investing Activities data on file, last reported at $191.1 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 1206.6% year-over-year to $191.1 million in Q1 2026; TTM through Mar 2026 was $203.9 million, a 241.36% increase from a year earlier, with the FY2025 full-year figure at $27.4 million, down 92.45% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $191.1 million, up from -$8.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for LAB reached as high as $318.1 million in Q1 2024 and fell as low as -$138.2 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged $30.2 million across 5 years, with a median of $14.6 million in 2025.
• Across the five-year window, Cash from Investing Activities sank 1419.96% in 2022 and soared 5071.66% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $40.2 million in 2022, then sank by 132.59% to -$13.1 million in 2023, then soared by 296.13% to $25.7 million in 2024, then slumped by 131.25% to -$8.0 million in 2025, then jumped by 2476.74% to $191.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $191.1 million in Q1 2026, -$8.0 million in Q4 2025, and -$6.7 million in Q3 2025.